[HTML][HTML] Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment

I Adini, K Ghosh, A Adini, ZL Chi… - The Journal of …, 2014 - Am Soc Clin Investig
The Journal of clinical investigation, 2014Am Soc Clin Investig
Studies have established that pigmentation can provide strong, protective effects against
certain human diseases. For example, angiogenesis-dependent diseases such as wet age-
related macular degeneration and infantile hemangioma are more common in light-skinned
individuals of mixed European descent than in African-Americans. Here we found that
melanocytes from light-skinned humans and albino mice secrete high levels of fibromodulin
(FMOD), which we determined to be a potent angiogenic factor. FMOD treatment stimulated …
Studies have established that pigmentation can provide strong, protective effects against certain human diseases. For example, angiogenesis-dependent diseases such as wet age-related macular degeneration and infantile hemangioma are more common in light-skinned individuals of mixed European descent than in African-Americans. Here we found that melanocytes from light-skinned humans and albino mice secrete high levels of fibromodulin (FMOD), which we determined to be a potent angiogenic factor. FMOD treatment stimulated angiogenesis in numerous in vivo systems, including laser-induced choroidal neovascularization, growth factor–induced corneal neovascularization, wound healing, and Matrigel plug assays. Additionally, FMOD enhanced vascular sprouting during normal retinal development. Deletion of Fmod in albino mice resulted in a marked reduction in the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, and Matrigel plugs. Our data implicate the melanocyte-secreted factor FMOD as a key regulator of angiogenesis and suggest an underlying mechanism for epidemiological differences between light-skinned individuals of mixed European descent and African-Americans. Furthermore, inhibition of FMOD in humans has potential as a therapeutic strategy for treating angiogenesis-dependent diseases.
The Journal of Clinical Investigation